Although there have been significant strides made in treating pediatric cancer, many children still succumb to their disease. Moreover, survivors can have detrimental late effects from their chemotherapy and radiation including abnormal growth, infertility, cardiac problems, and acquisition of secondary cancers. Therefore, improved and less toxic treatments are urgently needed. A common event leading to pediatric cancer is the breakage of two chromosome and swapping of genetic material between ends. These are called “balanced translocations” and lead to the generation of “fusion molecules” within the cancer cells. Characteristic fusion molecules occur in a wide array of pediatric cancers including leukemias (for example. MLL-AF9, RUNX1-ETV6, RUNX1-ETO) and solid tumors such as Ewing’s sarcoma (EWSR1-FLI1), rhabdomyosarcoma, and brain tumors. Importantly, the fusion molecules represent a unique “tag” that distinguishes the cancerous (or pre-cancerous) cells from the healthy cells. They also mark the most primitive cancer cells, which can sometimes fuel the relapse of a cancer following treatment. In 2023, a new technology was developed called “RADARS”, which senses whether a cell contains a specific mRNA sequence and, if so, deploys a payload protein. We hypothesize that RADARS can be developed to recognize specific "fusion molecules" in pediatric cancer cells and, if present, deploy a "suicide gene" to kill the cell.